Crossmark

Efficacy and safety of ziltivekimab in patients with chronic kidney disease susceptible to inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1186/s43094-024-00723-0

Published Online: 2024-11-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Elrosasy, Amr

Sabbagh, Dalal

Assaf, Mohammad

Tarakhan, Husam

Afyouni, Ahmad

Elgendy, Marwa O. https://orcid.org/0000-0002-5466-0552
Abdelaty, Lamiaa N.

Omar, Refaat H.

Zabady, Ahmed Hamdy
License Information

Text and Data Mining valid from 2024-11-26

Version of Record valid from 2024-11-26
More Information

Article History

Received: 26 May 2024

Accepted: 15 October 2024

First Online: 26 November 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no potential competing interests.

Document is current

Any future updates will be listed below